{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:49:57Z","timestamp":1772214597463,"version":"3.50.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Pyrexia is a frequent adverse event of BRAF\/MEK-inhibitor combination therapy in patients with metastasized malignant melanoma (MM). The study\u2019s objective was to identify laboratory changes which might correlate with the appearance of pyrexia. Initially, data of 38 MM patients treated with dabrafenib plus trametinib, of which 14 patients developed pyrexia, were analysed retrospectively. Graphical visualization of time series of laboratory values suggested that a rise in C-reactive-protein, in parallel with a fall of leukocytes and thrombocytes, were indicative of pyrexia. Additionally, statistical analysis showed a significant correlation between lactate dehydrogenase (LDH) and pyrexia. An algorithm based on these observations was designed using a deductive and heuristic approach in order to calculate a pyrexia score (PS) for each laboratory assessment in treated patients. A second independent data set of 28 MM patients, 8 with pyrexia, was used for the validation of the algorithm. PS based on the four parameters CRP, LDH, leukocyte and thrombocyte numbers, were statistically significantly higher in pyrexia patients, differentiated between groups (F = 20.8; p = &lt;0.0001) and showed a significant predictive value for the diagnosis of pyrexia (F = 6.24; p = 0.013). We provide first evidence that pyrexia in patients treated with BRAF\/MEK-blockade can be identified by an algorithm that calculates a score.<\/jats:p>","DOI":"10.1371\/journal.pone.0273478","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T13:41:19Z","timestamp":1661434879000},"page":"e0273478","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score"],"prefix":"10.1371","volume":"17","author":[{"given":"Hannah","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2704-4754","authenticated-orcid":true,"given":"Albert","family":"R\u00fcbben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Esser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0269-2819","authenticated-orcid":true,"given":"Arturo","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana-Diana","family":"Persa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marike","family":"Leijs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"pone.0273478.ref001","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjd.15510","article-title":"The global burden of melanoma: results from the Global Burden of Disease Study 2015","volume":"177","author":"C Karimkhani","year":"2017","journal-title":"Br J Dermatol"},{"key":"pone.0273478.ref002","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"O Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"pone.0273478.ref003","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"H Davies","year":"2002","journal-title":"Nature"},{"key":"pone.0273478.ref004","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3390\/cancers11111642","article-title":"Efficacy, safety, and tolerability of approved combination BRAF and MEK inhibitor regimens for BRAF-mutant melanoma","volume":"11","author":"O Hamid","year":"2019","journal-title":"Cancers"},{"key":"pone.0273478.ref005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"KT Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"pone.0273478.ref006","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"GV Long","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0273478.ref007","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"GV Long","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0273478.ref008","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/CMR.0000000000000110","article-title":"Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma","volume":"24","author":"CI Lee","year":"2014","journal-title":"Mel Res"},{"key":"pone.0273478.ref009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"HJ Gogas","year":"2019","journal-title":"Eur J Cancer"},{"key":"pone.0273478.ref010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"C Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0273478.ref011","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/annonc\/mdu529","article-title":"Characteristics of pyrexia in BRAFV600E\/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I\/II clinical trial","volume":"26","author":"AM Menzies","year":"2015","journal-title":"Ann Oncol"},{"key":"pone.0273478.ref012","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/1346-8138.14798","article-title":"Sudden elevation of plasma D-dimer levels induced by the combination therapy of dabrafenib and trametinib: Report of two cases","volume":"46","author":"S Akino","year":"2019","journal-title":"J Dermatol"},{"key":"pone.0273478.ref013","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/1346-8138.14949","article-title":"Dynamics of neutrophil and C-reactive protein reflect the clinical course of pyrexia during combination therapy with dabrafenib and trametinib","volume":"46","author":"T Maeda","year":"2019","journal-title":"J Dermatol"},{"key":"pone.0273478.ref014","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"SJ Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"pone.0273478.ref015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-019-03780-y","article-title":"Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia","volume":"83","author":"HY Kim","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0273478.ref016","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/CAD.0000000000000655","article-title":"Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection","volume":"29","author":"TD Clay","year":"2018","journal-title":"Anticancer Drugs"},{"key":"pone.0273478.ref017","doi-asserted-by":"crossref","first-page":"28294","DOI":"10.18632\/oncotarget.25511","article-title":"BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells","volume":"9","author":"E Hajek","year":"2018","journal-title":"Oncotarget"},{"key":"pone.0273478.ref018","doi-asserted-by":"crossref","first-page":"77","DOI":"10.31887\/DCNS.2012.14.1\/jmarewski","article-title":"Heuristic decision making in medicine","volume":"14","author":"JN Marewski","year":"2012","journal-title":"Dialogues Clin Neurosci"},{"key":"pone.0273478.ref019","volume-title":"Applied time series analysis: A practical guide to modeling and forecasting","author":"TC Mills","year":"2019"},{"key":"pone.0273478.ref020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jss.2017.07.010","article-title":"Refining a model for sustained usage of agile methodologies","volume":"132","author":"M Senapathi","year":"2017","journal-title":"J Syst Softw"},{"key":"pone.0273478.ref021","first-page":"230","article-title":"Procalcitonin, C-reactive protein and serum lactate dehydrogenase in the diagnosis of bacterial sepsis, SIRS and systemic candidiasis","volume":"23","author":"F Miglietta","year":"2015","journal-title":"Infez Med"},{"key":"pone.0273478.ref022","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer","volume":"33","author":"RB Corcoran","year":"2015","journal-title":"J Clin Oncol"},{"key":"pone.0273478.ref023","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"D Planchard","year":"2016","journal-title":"Lancet Oncol"},{"key":"pone.0273478.ref024","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2021.05.005","article-title":"Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers","volume":"153","author":"D Schadendorf","year":"2021","journal-title":"Eur J Cancer"},{"key":"pone.0273478.ref025","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.3390\/curroncol28050304","article-title":"Management of pyrexia associated with the combination of dabrafenib and trametinib: Canadian Consensus Statements","volume":"28","author":"A Thawer","year":"2021","journal-title":"Curr Oncol"},{"key":"pone.0273478.ref026","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejca.2021.12.015","article-title":"Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus","volume":"163","author":"V Atkinson","year":"2022","journal-title":"Eur J Cancer"},{"key":"pone.0273478.ref027","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors","volume":"14","author":"R Anforth","year":"2013","journal-title":"Lancet Oncol"},{"key":"pone.0273478.ref028","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1007\/s00520-019-4654-2","article-title":"Case series of dabrafenib-trametinib-induced pyrexia successfully treated with colchicine","volume":"27","author":"J Vera","year":"2019","journal-title":"Support Care Cancer"},{"key":"pone.0273478.ref029","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41467-020-15497-1","article-title":"Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation","volume":"11","author":"S Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"pone.0273478.ref030","doi-asserted-by":"crossref","first-page":"107615","DOI":"10.1016\/j.celrep.2020.107615","article-title":"Platelets fuel the inflammasome activation of innate immune cells","volume":"31","author":"V Rolfes","year":"2020","journal-title":"Cell Rep"},{"key":"pone.0273478.ref031","doi-asserted-by":"crossref","first-page":"e2858","DOI":"10.1371\/journal.pntd.0002858","article-title":"The role of platelets in the pathogenesis of viral hemorrhagic fevers","volume":"8","author":"JC Zapata","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"pone.0273478.ref032","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/09537104.2021.1952179","article-title":"Platelet-leukocyte interactions in the pathogenesis of viral infections","volume":"33","author":"ED Hottz","year":"2022","journal-title":"Platelets"},{"issue":"6","key":"pone.0273478.ref033","first-page":"S220","article-title":"Serum lactate and lactate dehydrogenase as parameters for the prediction of dengue severity","volume":"97","author":"P Sirikutt","year":"2014","journal-title":"J Med Assoc Thai"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T13:41:52Z","timestamp":1661434912000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0273478"}},"subtitle":[],"editor":[{"given":"Michael C.","family":"Burger","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0273478","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.29.22272913","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}